|
1
|
Dimitriou F, Krattinger R, Ramelyte E,
Barysch MJ, Micaletto S, Dummer R and Goldinger SM: The world of
melanoma: Epidemiologic, genetic, and anatomic differences of
melanoma across the globe. Curr Oncol Rep. 20:872018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carr S, Smith C and Wernberg J:
Epidemiology and risk factors of melanoma. Surg Clin North Am.
100:1–12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schadendorf D, van Akkooi ACJ, Berking C,
Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A and Ugurel
S: Melanoma. Lancet. 392:971–984. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lopez-Soto A, Gonzalez S, Smyth MJ and
Galluzzi L: Control of metastasis by NK cells. Cancer Cell.
32:135–154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhandaru M and Rotte A: Monoclonal
antibodies for the treatment of melanoma: Present and future
strategies. Methods Mol Biol. 1904:83–108. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McDermott D, Haanen J, Chen TT, Lorigan P
and O'Day S; MDX010-20 investigators, : Efficacy and safety of
ipilimumab in metastatic melanoma patients surviving more than 2
years following treatment in a phase III trial (MDX010-20). Ann
Oncol. 24:2694–2698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weiss SA, Wolchok JD and Sznol M:
Immunotherapy of melanoma: Facts and hopes. Clin Cancer Res.
25:5191–5201. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paluncic J, Kovacevic Z, Jansson PJ,
Kalinowski D, Merlot AM, Huang MLH, Lok HC, Sahni S, Lane DJR and
Richardson DR: Roads to melanoma: Key pathways and emerging players
in melanoma progression and oncogenic signaling. Biochim Biophys
Acta. 1863:770–784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ankeny JS, Labadie B, Luke J, Hsueh E,
Messina J and Zager JS: Review of diagnostic, prognostic, and
predictive biomarkers in melanoma. Clin Exp Metastasis. 35:487–493.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Karagiannis P, Fittall M and Karagiannis
SN: Evaluating biomarkers in melanoma. Front Oncol.
4:3832015.PubMed/NCBI
|
|
11
|
Sun J, Zhang D, Bae DH, Sahni S, Jansson
P, Zheng Y, Zhao Q, Yue F, Zheng M, Kovacevic Z and Richardson DR:
Metastasis suppressor, NDRG1, mediates its activity through
signaling pathways and molecular motors. Carcinogenesis.
34:1943–1954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smalley MJ and Dale TC: Wnt signalling in
mammalian development and cancer. Cancer Metastasis Rev.
18:215–230. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng L and Pan J: The anti-malarial drug
artesunate blocks wnt/beta-catenin pathway and inhibits growth,
migration and invasion of uveal melanoma cells. Curr Cancer Drug
Targets. 18:988–998. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sinnberg T, Levesque MP, Krochmann J,
Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C and Busch
C: Wnt-signaling enhances neural crest migration of melanoma cells
and induces an invasive phenotype. Mol Cancer. 17:592018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gearhart J, Pashos EE and Prasad MK:
Pluripotency redux-advances in stem-cell research. N Engl J Med.
357:1469–1472. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meškytė EM, Keskas S and Ciribilli Y: MYC
as a multifaceted regulator of tumor microenvironment leading to
metastasis. Int J Mol Sci. 21:77102020. View Article : Google Scholar
|
|
18
|
Lin X, Sun R, Zhao X, Zhu D, Zhao X, Gu Q,
Dong X, Zhang D, Zhang Y, Li Y and Sun B: C-myc overexpression
drives melanoma metastasis by promoting vasculogenic mimicry via
c-myc/snail/Bax signaling. J Mol Med (Berl). 95:53–67. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishikawa S, Ishii H, Haraguchi N, Kano Y,
Fukusumi T, Ohta K, Ozaki M, Dewi DL, Sakai D, Satoh T, et al:
microRNA-based cancer cell reprogramming technology. Exp Ther Med.
4:8–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Noori J, Sharifi M and Haghjooy Javanmard
S: miR-30a inhibits melanoma tumor metastasis by targeting the
E-cadherin and zinc finger E-box binding homeobox 2. Adv Biomed
Res. 7:1432018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pencheva N, Tran H, Buss C, Huh D,
Drobnjak M, Busam K and Tavazoie SF: Convergent multi-miRNA
targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis
and angiogenesis. Cell. 151:1068–1082. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gajos-Michniewicz A and Czyz M: Role of
miRNAs in melanoma metastasis. Cancers (Basel). 11:3262019.
View Article : Google Scholar
|
|
25
|
Sole C, Tramonti D, Schramm M, Goicoechea
I, Armesto M, Hernandez LI, Manterola L, Fernandez-Mercado M,
Mujika K, Tuneu A, et al: The circulating transcriptome as a source
of biomarkers for melanoma. Cancers (Basel). 11:702019. View Article : Google Scholar
|
|
26
|
Wang X, Zou M, Li J, Wang B, Zhang Q, Liu
F and Lü G: LncRNA H19 targets miR-22 to modulate H2O2-induced
deregulation in nucleus pulposus cell senescence, proliferation,
and ECM synthesis through Wnt signaling. J Cell Biochem.
119:4990–5002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
ELife. 4:e050052015. View Article : Google Scholar
|
|
28
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Team RC: R: A language and environment for
statistical computing. R Foundation for Statistical Computing;
Vienna: 2013
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Javanmard SH, Vaseghi G, Ghasemi A, Rafiee
L, Ferns GA, Esfahani HN and Nedaeinia R: Therapeutic inhibition of
microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and
its effects on the biological behaviors of melanoma cancer cells in
preclinical studies. Cancer Cell Int. 20:3842020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lorusso C, De Summa S, Pinto R, Danza K
and Tommasi S: miRNAs as key players in the management of cutaneous
melanoma. Cells. 9:4152020. View Article : Google Scholar
|
|
33
|
Kunz M: MicroRNAs in melanoma biology. Adv
Exp Med Biol. 774:103–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qian H, Yang C and Yang Y: MicroRNA-26a
inhibits the growth and invasiveness of malignant melanoma and
directly targets on MITF gene. Cell Death Discov. 3:170282017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ryu B, Hwang S and Alani RM: MicroRNAs as
an emerging target for melanoma therapy. J Invest Dermatol.
133:1137–1139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hanniford D, Zhong J, Koetz L,
Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro R, Berman
R, Darvishian F, et al: A miRNA-based signature detected in primary
melanoma tissue predicts development of brain metastasis. Clin
Cancer Res. 21:4903–4912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu S, Tetzlaff MT, Cui R and Xu X:
miR-200c inhibits melanoma progression and drug resistance through
down-regulation of BMI-1. Am J Pathol. 181:1823–1835. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ishteiwy RA, Ward TM, Dykxhoorn DM and
Burnstein KL: The microRNA-23b/-27b cluster suppresses the
metastatic phenotype of castration-resistant prostate cancer cells.
PLoS One. 7:e521062012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee JJ, Drakaki A, Iliopoulos D and Struhl
K: MiR-27b targets PPARg to inhibit growth, tumor progression and
the inflammatory response in neuroblastoma cells. Oncogene.
31:3818–3825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z,
Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular
endothelial growth factor C to inhibit tumor progression and
angiogenesis in colorectal cancer. PLoS One. 8:e606872013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Campbell KJ and White RJ: MYC regulation
of cell growth through control of transcription by RNA polymerases
I and III. Cold Spring Harb Perspect Med. 4:a0184082014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Q, Spears E, Boone DN, Li Z, Gregory
MA and Hann SR: Domain-specific c-Myc ubiquitylation controls c-Myc
transcriptional and apoptotic activity. Proc Natl Acad Sci USA.
110:978–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kong LM, Liao CG, Zhang Y, Xu J, Li Y,
Huang W, Zhang Y, Bian H and Chen ZN: A regulatory loop involving
miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer
invasion and metastasis. Cancer Res. 74:3764–3778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang L, Hou Y, Ashktorab H, Gao L, Xu Y,
Wu K, Zhai J and Zhang L: The impact of C-MYC gene expression on
gastric cancer cell. Mol Cell Biochem. 344:125–135. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Poźniak J, Nsengimana J, Laye JP, O'Shea
SJ, Diaz JMS, Droop AP, Filia A, Harland M, Davies JR, Mell T, et
al: Genetic and environmental determinants of immune response to
cutaneous melanoma. Cancer Res. 79:2684–2696. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mannava S, Grachtchouk V, Wheeler LJ, Im
M, Zhuang D, Slavina EG, Mathews CK, Shewach DS and Nikiforov MA:
Direct role of nucleotide metabolism in C-MYC-dependent
proliferation of melanoma cells. Cell Cycle. 7:2392–2400. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen Y, Bathula SR, Yang Q and Huang L:
Targeted nanoparticles deliver siRNA to melanoma. J Invest
Dermatol. 130:2790–2798. 2010. View Article : Google Scholar : PubMed/NCBI
|
